Is Tilray stock a Buy? TLRY soars over 16% amid optimism about US cannabis regulatory changes and European expansion

Tilray stock today: Tilray Brands Inc. (TLRY) is starting the week with a bang as the cannabis company’s stock jumped 16% on Monday to $1.34, after a fresh wave of optimism swept through the industry due to potential regulatory changes in US, and Wall Street took notice, according to the report.

Jefferies Upgrades Tilray Price Target Amid Industry Buzz

Helping fuel Tilray's stock rally was a positive note from Jefferies by analyst Kaumil Gajrawala, who maintained a Buy rating on the stock while raising the price target from $1.50 to $2, as per a Benzinga report.

Trump Administration Expected to Reclassify Marijuana

This comes as the US president Donald Trump is expected to soon reclassify marijuana, making it less dangerous and also potentially simplifying cannabis processes, which could immediately change the cannabis markets, according to a Stockstotrade report.


ALSO READ: Rocket Lab stock jumps over 9% after expansion of US manufacturing and 70th Electron mission launch

What Reclassification Means for Cannabis Companies

The proposed reclassification of marijuana is expected to move from Schedule I to Schedule III, which would drastically reduce federal restrictions and open new pathways for medical cannabis access and for firms like Tilray, this regulatory change could eliminate many of the banking, tax, and operational hurdles that have impacted the industry for years, as reported by Rollingout.

However, Jefferies pointed out that this potential change falls short of full legalization, but it is a significant progress as Congress reviews bills related to banking, access, and reform in the cannabis sector, according to Investing.com report. The investment firm also highlighted that rescheduling could provide benefits like lower taxes and easier research opportunities for cannabis companies, as per the report.

ALSO READ: When are Nvidia earnings and what Wall Street expects from the $3 trillion AI giant?

Tilray Expands in Europe Through Italian Partnership

Apart from the domestic policy developments, Tilray has also revaled about a strategic partnership with Italian pharmaceutical company Molteni to expand its European market presence, as reported by Rollingout. The firm's international expansion comes as European cannabis markets continue to mature, with Germany driving the charge in medical cannabis adoption, according to the report.

The European venture is Tilray’s broader strategy to diversify geographically and reduce dependence on the volatile North American market as company executives have previously highlighted that international markets offer more stable regulatory environments and potentially higher profit margins compared to the increasingly competitive Canadian and US markets, as reported by Rollingout.

FAQs

Why did Tilray stock go up?
Tilray stock rose on Monday due to optimism around US cannabis reform and a strategic expansion into European markets, as per the Rollingout report.

What did Jefferies say about Tilray?
Jefferies maintained a Buy rating on Tilray and raised its price target from $1.50 to $2, due to potential benefits from regulatory changes, as per the Benzinga report.